|
|
Oncology Drug Development World Europe 2008
Venue
The Hilton London Euston Hotel
Pre-conference workshop
14 October 10.30am - 4:00pm
Day 1
15 October 8.30am - 5:30pm
Day 2
16 October 8.30am - 5:30pm
London, United Kingdom
|
|
|
|
Meet our speakers
|
|
|
Vice President, Global Supportive Care,
Amgen
Roy Baynes is Vice President, and Therapeutic Area Head for Oncology in Supportive Care, Clinical Development at Amgen Inc., Thousand Oaks, California, USA. Previous roles at Amgen have included GDL for Neulasta, GDL for Panitumumab, and TA Head for Medical Affairs Oncology. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, South Africa. Dr Baynes has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. Dr Baynes has been recurrently named among America’s top physicians. Before joining Amgen in his current role in 2002, he was Director of the Bone Marrow Transplant Program, the Stem Cell Biology Program, the JP McCarthy Umbilical Cord Stem Cell Bank and the Hematological Malignancies Multidisciplinary Clinic at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.
|
|
Vice President and Global Head Business Development,
Roche
Warwick leads the Business Development team within Pharma Partnering. His team of roughly twenty, spearheads Roche’s external search and evaluation and interfaces potential partners with the wider Roche organisation – from scientists to senior management. Within Pharma Partnering, the Business Development team works closely with the Licensing and Alliance Management teams to optimize deal negotiations, contracting and building relationships for partnerships that will succeed in the longterm. Before taking up his current role with Pharma Partnering in New Jersey, Warwick was General Manager for Roche Philippines. Warwick initially joined Roche in 1998 in his home country Australia, where he held a variety of senior sales and marketing positions across the primary care and specialty care portfolios. Prior to Roche, Warwick held positions of increasing responsibility at Schering-Plough in Australia and Asia and other healthcare-related companies in Australia. Since 2006, Warwick has been a member of the Board of European Chamber of Commerce of the Philippines and the Pharmaceutical and Healthcare Association of The Philippines. He is also a member of the Pharmaceutical Society of Australia and the Australian College of Pharmacy Practice. In March 2007 he was elected a member of the Board of the New York Pharma Forum. Warwick has a PharmD from the University of Sydney, Australia and a Masters in Business Administration and a Post-Graduate Diploma in Marketing from the University of Technology, Sydney, Australia.
|
|
Senior Director and Head, Licensing and External Research, Europe,
Merck Sharp & Dohme
Margaret Beer studied at the University of Reading (Zoology) and at the University of London (Biochemistry) before carrying out her research work on serotonin pharmacology, leading to the award of her Ph.D, under the supervision of Prof. Derek Middlemiss. She joined Merck, as a neuroscientist, in 1984 following her return to the UK from Stanford University.
She is one of the founding members of the team responsible for the development of Merck’s anti-migraine drug MAXALT and was involved in the project during the basic research stage through to the launch in 1997. Her other main areas of research interest include depression, anxiety and multiple sclerosis. Margaret joined the Worldwide Licensing and External Research, Europe, group, under the leadership of Dr Ray Hill, in 2003. This group was established in 2002 specifically in recognition of the scientific excellence in Europe and the wealth of potential licensing opportunities. Margaret assumed leadership of the group in 2008 following the retirement of Ray Hill. She is the co-author of 100 original research articles, review articles, and abstracts, and has presented widely at international professional meetings.
|
|
Director, Experimental Medicine,
Merck & Co
Dr. Bergstrom has been involved in a number of aspects of oncology drug development at Merck Research Labs since joining the company in 2004. His responsibilities have included incorporating gene expression technologies into oncology clinical trials, designing proof-of-concept strategies for novel therapeutic mechanisms, and authoring Phase I through IIa clinical trials. Since February 2007 he has been Director and Oncology Franchise Lead in the Experimental Medicine department at Merck. The Experimental Medicine Oncology group is focused on improving the probability of success of development of novel targeted oncology drugs. The group works closely with scientists from other Merck departments, academia and biotech to translate novel biological insights and research tools into clinical trial paradigms fit for decision-making. Areas of research include: gene expression biomarkers for patient selection; biomarkers for establishing proof-of-biology in small, focused clinical trials; and functional imaging biomarkers. Prior to joining Merck he trained in Laboratory Medicine at the University of Washington and was a post-doctoral associate at the Fred Hutchinson Cancer Research Center, both in Seattle, Washington. Dr. Bergstrom received his PhD and MD degrees through the Medical Scientist Training Program at the University of Washington.
|
|
Chief Scientific Officer,
Transgene
Dr Jean-Yves Bonnefoy, VP, Research and Development was appointed Vice President, Research in February 2005 and Vice President, Research and Development in March 2006 in charge of Research, Clinical Development, Regulatory Affairs and Intellectual Property. Prior to joining Transgene, he was Head of the Canceropôle Lyon Rhônes-Alpes. From 1997 to 2002, he was Director of the Immunology Center of the Pierre Fabre Group in Saint-Julien en Genevois, France. He previously was responsible for the Immunology Department of the Biomedical Research Institute of the Glaxo-Wellcome Group in Geneva, Switzerland. Jean-Yves Bonnefoy holds a PhD in immunology from the Lyons Claude Bernard University and has completed the Senior Management Program of the London Business School.
|
|
Clinical Development Director, Oncology: Early Phase,
Astrazeneca
Dr Glen Clack is the Associate Director of Discovery Medicine for Cancer and Infection based at AstraZeneca Alderley Park. This role involves overseeing the translational research programmes supporting over 30 products in late phase discovery and all phases of clinical development. He graduated from the Royal Free Hospital School of Medicine, London, spending 5 years in basic surgical training in the National Health Service. He joined Zeneca in 1997, and has experience in all phases of clinical development within Oncology. Since 2002 he has been involved in Translational Science and Phase I studies with small molecule tyrosine kinase inhibitors, and has developed biomarkers that provided proof of mechanism and proof of principle of action. Within the industry, he also has had responsibilities on the Oncology Target Selection Team, and is the AstraZeneca nominated representative for several Academic and Regulatory Alliances/’Think Tanks’. He also holds an honorary academic position within the Section of Human Metabolism of the Faculty of Medicine at the University of Sheffield, where he is writing his MD thesis; entitled ‘The use of bone turnover markers in drug development’.
|
|
Statistical Expert,
Roche Products Limited
After graduating, Simon spent 5 years in the University of London doing research and teaching in medical schools. In 1990 he joined the pharmaceutical industry: first Eli Lilly heading a small group of statisticians and data managers at their European office and then in 1994 he moved to the UK office of Leo Pharmaceuticals heading a similar group. At the beginning of 2002 he joined the Medicines Control Agency (now Medicines and Healthcare products Regulatory Agency), initially as Statistics Unit Manager and later taking on responsibility for managing the assessment of all gastrointestinal, nutritional and blood therapies. He was also vice-Chairman of the CHMP Scientific Advice Working Party. In November 2006 he joined Roche as a statistical expert advising on statistical, clinical trials and regulatory matters throughout the company. Simon is a former president of the International Society for Clinical Biostatistics; he is an associate editor of Statistics in Medicine, on the editorial board of Pharmaceutical Statistics and is the Read Papers Consulting Editor for the Journal of the Royal Statistical Society. He has also served on the editorial boards of Controlled Clinical Trials and JRSS Series A. He has published widely in statistical and medical journals, is author of one book ‘Dictionary for Clinical Trials’ published by Wiley in 1999 (2nd edition 2007) and is joint editor of the ‘Textbook of Clinical Trials’ published by Wiley in 2004 (2nd edition 2006). He is an Honorary Research Fellow at Napier University in Edinburgh from where he gained his PhD by Published Work in 2004; a member of the External Advisory Panel for the Department of Statistics at Oxford University; an external examiner at the University of Kingston in London; an Associate on the faculty of the Johns Hopkins University in Baltimore; and a regular lecturer and member of the Educational Advisory Board at the Vienna School of Clinical Research in Austria. He also serves on the Hammersmith and Chelsea Hospitals Research Ethics Committee in London.
|
|
Business Unit Director,
Amgen
John de Wit has worked in the pharmaceutical industry since his training as a pharmacist at State University of Utrecht, the Netherlands. He has 17 years of experience in the secondary care environment at Glaxo (Netherlands) and Brocacef (a top-3 wholesaler where he was responsible for the marketing of generics and Parallel Trade). John joined Amgen (Netherlands) in 1996. SInce 2006 John has been the UK & Ireland Director for the Oncology Business Unit and is based in Cambridge (UK). Previously John was the International Brand Director at Amgen's International Headquarters in Zug, Switzerland. Throughout his 17 years have been in the Oncology & Haematology therapeutic areas, where his interest and passion is deep rooted. Working in a disease type where continuous and significant progress is being made and where your personal activity contributes to improving the lives of patients with grievous illnesses is his main driver to get him out of bed in the morning.
|
|
Vice President Translational Science & Head of Oncology,
Medimmune
|
|
Head of Clinical Partnerships,
Cancer Research UK
|
|
Managing Director,
Cancer Deals
Brian Lovatt spent 25 years in the pharmaceutical industry working in clinical research and development, sales and marketing, and senior management and international management positions. Brian now runs the International research and consultancy practice Vision Healthcare. Cancer Research, Development and dealmaking is a specialist interest of the company which has the services of one of the top oncologists and researchers to help companies deliver their products through the market access hurdles so that patients can have access to treatments.
|
|
Director of Project Devt & Scientific Affairs,
Orion Clinical Services Ltd
Peter MacLennan began his career in the academic field with a PhD in Physiology from Dundee University. Following post-doctoral work at the University of London he was appointed Research Fellow and subsequently Lecturer at Liverpool University. He moved to the Pharmaceutical Industry in 1992 joining Solvay Healthcare in the Clinical Development Group. Since 1996 he has held a variety of business and operational roles in Clinical Research Organisations. He has been with ORION Clinical Services for the past 6 years – his responsibilities there include managing the German Business Unit and the Biometrics teams – he also leads the European Business Development Group.
|
|
Director,
Cancer Intelligence
Gordon McVie is a medical oncologist now working part time as Senior Consultant at the European Institute of Oncology in Milan. He is also Director of Cancer Intelligence which publishes the new online Open Access cancer journal, ecancermedicalscience.com. An Edinburgh medical graduate, he was made a Senior Lecturer and consultant oncologist in Glasgow, in 1975. From 1979 to 1989 he was Clinical Research Director at the National Cancer Institute, Amsterdam, then from 1989 to 2002- Scientific Director and Director General of Cancer Research Campaign, UK. In 2002 he led the merger which formed Cancer Research UK. He has a research passion in new drug development, and clinical interests cover breast, ovary, lung, prostate, brain and lymphomatous cancer. He has authored around 300 scientific articles and books, and has held over a dozen visiting professorships – currently Cardiff and Glasgow Universities. For eight years he chaired the Fellowships Programme of the UICC, Geneva, and has held various positions at EORTC, Brussels, including Treasurer and President. He was European Editor of the Journal of the National Cancer Institute for ten years.
|
|
Senior Director, Oncology Clinical Development ,
Novartis Pharmaceuticals Corporation
|
|
Associate Director, Regulatory Affairs Oncology,
Eli Lilly & Co
Colleen Mockbee is Associate Director of U.S. Regulatory Affairs at Eli Lilly and Company Ms. Mockbee specializes in the field of regulatory oncology drug development. Her in depth knowledge of U.S. policy, regulations, and regulatory precedent provide the foundation on which she guides teams to build successful oncology drug development plans from first in human through registration and commercialization. She has over 10 years of drug development experience including preparing teams for FDA and advisory committee meetings as well as successful registration of new indications for commercial products. She is a pharmacist by training. Prior to joining Eli Lilly she worked as a pharmacist in the Veteran’s Administration hospital and clinics, and as a sales representative for Merck & Co.
|
|
Medical Science Director,
Astrazeneca
Clive is currently the Director for Late Stage Oncology within Clinical Development at AstraZeneca. Over the last 6 years, he has held roles across the spectrum of drug development in Oncology from interaction with drug discovery to maximizing brand value of products near patent expiry. Prior to joining AstraZeneca, he trained in surgery leading to accreditation by the Royal College of Surgeons of England, and subsequently gained a Doctorate of Medicine research degree in molecular mechanisms involved in upper gastrointestinal cancer development. Clive also holds an Executive MBA and is accredited as a specialist Pharmaceutical Physician by the UK General Medical Council.
|
|
Vice President of Research,
Merrimack Pharmaceuticals
|
|
Director,Oncology Medicine Development Center,
GlaxoSmithKline
"Director of Oncology at GlaxoSmithKline Medicne Development Cetre at Stockley park in the UK. She received her MD degree and diploma of specialisatin in Oncology from the University of Genoa, Italy. She continued her medical training with residencies in medical oncology at the National Institute for Cancer Research (Genoa, Italy) and received fellowships at the European Organisation for Research and Treatment of Cancer (Brussels, Belgium) and at the European Institute of Oncology (Milan, Italy). Dr Oliva has many years of experience in the clinical development of oncology drugs such as gemcitabine, and has pursued research activities in clinical oncology with a special focus in breast cancer. She is currently responsible for GSK's clinical development programme of lapatinib worldwide".
|
|
Global Head, Oncology Imaging,
Novartis Pharmaceuticals Corporation
|
|
Expert Medical Assessor,
Medicines and Healthcare Products Regulatory Agency (MHRA)
|
|
Head of Translational Medicine Group,
GlaxoSmithKline
Richard Wooster initially focused on the discovery of cancer susceptibility genes, for example mapping and cloning the breast cancer susceptibility gene BRCA2. After this he realised the power of the human genome sequence as a tool to uncover the many somatic mutations that occur in cancer and in 2000 initiated the Cancer Genome Project at the Wellcome Trust Sanger Institute, a project that has since been mirrored by the NCI This revealed, for the first time, somatic mutations in BRAF and ERBB2. Richard was the founder of the COSMIC database and web site of somatic mutations in cancer. Currently Richard is Director and Head of Oncology Translational Medicine at GSK where he is driving the clinical development of oncology therapies through robust pre-clinical experiments.
|
|
|
|
|
|
|
